DBV Technologies
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.56
- Today's High:
- $1.66
- Open Price:
- $1.66
- 52W Low:
- $1.08
- 52W High:
- $3.43
- Prev. Close:
- $1.61
- Volume:
- 30957
Company Statistics
- Market Cap.:
- $295.64 million
- Book Value:
- 1.0345
- Revenue TTM:
- $4.84 million
- Operating Margin TTM:
- -1994.86%
- Gross Profit TTM:
- $4.84 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.72%
- Return on Equity TTM:
- -65.55%
Company Profile
DBV Technologies had its IPO on 2014-10-22 under the ticker symbol DBVT.
The company operates in the Healthcare sector and Biotechnology industry. DBV Technologies has a staff strength of 85 employees.
Stock update
Shares of DBV Technologies opened at $1.66 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $1.56 - $1.66, and closed at $1.58.
This is a -1.86% slip from the previous day's closing price.
A total volume of 30,957 shares were traded at the close of the day’s session.
In the last one week, shares of DBV Technologies have increased by +0.64%.
DBV Technologies's Key Ratios
DBV Technologies has a market cap of $295.64 million, indicating a price to book ratio of 1.356 and a price to sales ratio of 28.1487.
In the last 12-months DBV Technologies’s revenue was $4.84 million with a gross profit of $4.84 million and an EBITDA of $-83469000. The EBITDA ratio measures DBV Technologies's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, DBV Technologies’s operating margin was -1994.86% while its return on assets stood at -30.72% with a return of equity of -65.55%.
In Q4, DBV Technologies’s quarterly earnings growth was a positive 0% while revenue growth was a positive 56.8%.
DBV Technologies’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into DBV Technologies’s profitability.
DBV Technologies stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.9891. Its price to sales ratio in the trailing 12-months stood at 28.1487.
DBV Technologies stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $246.52 million
- Total Liabilities
- $29.52 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $12000
- Dividend Payout Ratio
- 0%
DBV Technologies ended 2023 with $246.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $246.52 million while shareholder equity stood at $194.45 million.
DBV Technologies ended 2023 with $0 in deferred long-term liabilities, $29.52 million in other current liabilities, in common stock, $-259578000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $209.19 million and cash and short-term investments were $209.19 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
DBV Technologies’s total current assets stands at $223.07 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $14.47 million and inventory worth $0.
In 2023, DBV Technologies's operating cash flow was $0 while its capital expenditure stood at $12000.
Comparatively, DBV Technologies paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.58
- 52-Week High
- $3.43
- 52-Week Low
- $1.08
- Analyst Target Price
- $5.09
DBV Technologies stock is currently trading at $1.58 per share. It touched a 52-week high of $3.43 and a 52-week low of $3.43. Analysts tracking the stock have a 12-month average target price of $5.09.
Its 50-day moving average was $1.45 and 200-day moving average was $1.82 The short ratio stood at 19.23 indicating a short percent outstanding of 0%.
Around 19.7% of the company’s stock are held by insiders while 2821.8% are held by institutions.
Frequently Asked Questions About DBV Technologies
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn’s disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.